Tofersen (previously known as BIIB067) targets superoxide dismutase (SOD1) in ALS patients, reducing SOD1 concentrations in spinal fluid to preserve motor neurons and slow the progression of the disease. The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.